Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
35
CZMWY Quote, Financials, Valuation and Earnings
Last price:
$31.84
Seasonality move
:
8.14%
Day range:
$31.39 - $32.29
52-week range:
$29.92 - $76.28
Dividend yield:
2.03%
P/E ratio:
17.75x
P/S ratio:
1.13x
P/B ratio:
3.11x
Volume:
2.2K
Avg. volume:
7.4K
1-year change:
-44.7%
Market cap:
$2.8B
Revenue:
$2.5B
EPS (TTM):
$1.79
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CZMWY
Carl Zeiss Meditec AG
|
-- | -- | -- | -- | -- |
|
BNTX
BioNTech SE
|
$516.2M | -$2.00 | 93.93% | -31.18% | $139.12 |
|
CVAC
CureVac NV
|
$15.4M | -$0.11 | 0.04% | -32.36% | $5.31 |
|
IFRX
InflaRx NV
|
$8.4K | -$0.14 | -74.55% | -70.4% | $10.46 |
|
IMTX
Immatics NV
|
$13.5M | -$0.50 | -81.87% | -704.25% | $19.13 |
|
MDGEF
Medigene AG
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CZMWY
Carl Zeiss Meditec AG
|
$31.84 | -- | $2.8B | 17.75x | $0.65 | 2.03% | 1.13x |
|
BNTX
BioNTech SE
|
$110.15 | $139.12 | $27.6B | 191.55x | $0.00 | 0% | 7.49x |
|
CVAC
CureVac NV
|
$4.66 | $5.31 | $1B | 6.52x | $0.00 | 0% | 12.94x |
|
IFRX
InflaRx NV
|
$0.89 | $10.46 | $60.6M | -- | $0.00 | 0% | 276.31x |
|
IMTX
Immatics NV
|
$10.06 | $19.13 | $1.2B | 42.21x | $0.00 | 0% | 13.44x |
|
MDGEF
Medigene AG
|
-- | -- | -- | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CZMWY
Carl Zeiss Meditec AG
|
-- | -0.790 | -- | 1.10x |
|
BNTX
BioNTech SE
|
1.31% | 1.308 | 1.22% | 6.78x |
|
CVAC
CureVac NV
|
3.87% | 2.704 | 3.39% | 1.84x |
|
IFRX
InflaRx NV
|
2.1% | -0.262 | 1.26% | 2.34x |
|
IMTX
Immatics NV
|
3.78% | 2.067 | 1.86% | 6.97x |
|
MDGEF
Medigene AG
|
-- | 0.000 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CZMWY
Carl Zeiss Meditec AG
|
$328.5M | $60.2M | 7.37% | 7.44% | 8.67% | $108.3M |
|
BNTX
BioNTech SE
|
$1.6B | $743.4M | -2.96% | -3.01% | 41.89% | $785.5M |
|
CVAC
CureVac NV
|
$57.9M | -$11.6M | 19.52% | 20.55% | -18.33% | $31.6M |
|
IFRX
InflaRx NV
|
-$89.2K | -$11.7M | -80.95% | -82.01% | -42057.91% | -$11.4M |
|
IMTX
Immatics NV
|
-- | -$63.9M | -24.18% | -25.21% | -1053.82% | -$56.2M |
|
MDGEF
Medigene AG
|
-- | -- | -- | -- | -- | -- |
Carl Zeiss Meditec AG vs. Competitors
-
Which has Higher Returns CZMWY or BNTX?
BioNTech SE has a net margin of 5.16% compared to Carl Zeiss Meditec AG's net margin of -1.89%. Carl Zeiss Meditec AG's return on equity of 7.44% beat BioNTech SE's return on equity of -3.01%.
Company Gross Margin Earnings Per Share Invested Capital CZMWYCarl Zeiss Meditec AG52.71% $0.36 $2.3B BNTXBioNTech SE90.24% -$0.14 $22B -
What do Analysts Say About CZMWY or BNTX?
Carl Zeiss Meditec AG has a consensus price target of --, signalling downside risk potential of --. On the other hand BioNTech SE has an analysts' consensus of $139.12 which suggests that it could grow by 26.31%. Given that BioNTech SE has higher upside potential than Carl Zeiss Meditec AG, analysts believe BioNTech SE is more attractive than Carl Zeiss Meditec AG.
Company Buy Ratings Hold Ratings Sell Ratings CZMWYCarl Zeiss Meditec AG0 0 0 BNTXBioNTech SE14 5 0 -
Is CZMWY or BNTX More Risky?
Carl Zeiss Meditec AG has a beta of 1.647, which suggesting that the stock is 64.66% more volatile than S&P 500. In comparison BioNTech SE has a beta of 1.488, suggesting its more volatile than the S&P 500 by 48.755%.
-
Which is a Better Dividend Stock CZMWY or BNTX?
Carl Zeiss Meditec AG has a quarterly dividend of $0.65 per share corresponding to a yield of 2.03%. BioNTech SE offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Carl Zeiss Meditec AG pays 18.62% of its earnings as a dividend. BioNTech SE pays out -- of its earnings as a dividend. Carl Zeiss Meditec AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CZMWY or BNTX?
Carl Zeiss Meditec AG quarterly revenues are $623.3M, which are smaller than BioNTech SE quarterly revenues of $1.8B. Carl Zeiss Meditec AG's net income of $32.2M is higher than BioNTech SE's net income of -$33.5M. Notably, Carl Zeiss Meditec AG's price-to-earnings ratio is 17.75x while BioNTech SE's PE ratio is 191.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Carl Zeiss Meditec AG is 1.13x versus 7.49x for BioNTech SE. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CZMWYCarl Zeiss Meditec AG1.13x 17.75x $623.3M $32.2M BNTXBioNTech SE7.49x 191.55x $1.8B -$33.5M
-
Which has Higher Returns CZMWY or CVAC?
CureVac NV has a net margin of 5.16% compared to Carl Zeiss Meditec AG's net margin of -5832.47%. Carl Zeiss Meditec AG's return on equity of 7.44% beat CureVac NV's return on equity of 20.55%.
Company Gross Margin Earnings Per Share Invested Capital CZMWYCarl Zeiss Meditec AG52.71% $0.36 $2.3B CVACCureVac NV91.57% $1.41 $1.1B -
What do Analysts Say About CZMWY or CVAC?
Carl Zeiss Meditec AG has a consensus price target of --, signalling downside risk potential of --. On the other hand CureVac NV has an analysts' consensus of $5.31 which suggests that it could grow by 14.28%. Given that CureVac NV has higher upside potential than Carl Zeiss Meditec AG, analysts believe CureVac NV is more attractive than Carl Zeiss Meditec AG.
Company Buy Ratings Hold Ratings Sell Ratings CZMWYCarl Zeiss Meditec AG0 0 0 CVACCureVac NV1 3 0 -
Is CZMWY or CVAC More Risky?
Carl Zeiss Meditec AG has a beta of 1.647, which suggesting that the stock is 64.66% more volatile than S&P 500. In comparison CureVac NV has a beta of 1.877, suggesting its more volatile than the S&P 500 by 87.704%.
-
Which is a Better Dividend Stock CZMWY or CVAC?
Carl Zeiss Meditec AG has a quarterly dividend of $0.65 per share corresponding to a yield of 2.03%. CureVac NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Carl Zeiss Meditec AG pays 18.62% of its earnings as a dividend. CureVac NV pays out -- of its earnings as a dividend. Carl Zeiss Meditec AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CZMWY or CVAC?
Carl Zeiss Meditec AG quarterly revenues are $623.3M, which are larger than CureVac NV quarterly revenues of $63.3M. Carl Zeiss Meditec AG's net income of $32.2M is lower than CureVac NV's net income of $319.3M. Notably, Carl Zeiss Meditec AG's price-to-earnings ratio is 17.75x while CureVac NV's PE ratio is 6.52x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Carl Zeiss Meditec AG is 1.13x versus 12.94x for CureVac NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CZMWYCarl Zeiss Meditec AG1.13x 17.75x $623.3M $32.2M CVACCureVac NV12.94x 6.52x $63.3M $319.3M
-
Which has Higher Returns CZMWY or IFRX?
InflaRx NV has a net margin of 5.16% compared to Carl Zeiss Meditec AG's net margin of -51538.49%. Carl Zeiss Meditec AG's return on equity of 7.44% beat InflaRx NV's return on equity of -82.01%.
Company Gross Margin Earnings Per Share Invested Capital CZMWYCarl Zeiss Meditec AG52.71% $0.36 $2.3B IFRXInflaRx NV-320.86% -$0.21 $54.4M -
What do Analysts Say About CZMWY or IFRX?
Carl Zeiss Meditec AG has a consensus price target of --, signalling downside risk potential of --. On the other hand InflaRx NV has an analysts' consensus of $10.46 which suggests that it could grow by 1068.88%. Given that InflaRx NV has higher upside potential than Carl Zeiss Meditec AG, analysts believe InflaRx NV is more attractive than Carl Zeiss Meditec AG.
Company Buy Ratings Hold Ratings Sell Ratings CZMWYCarl Zeiss Meditec AG0 0 0 IFRXInflaRx NV5 2 0 -
Is CZMWY or IFRX More Risky?
Carl Zeiss Meditec AG has a beta of 1.647, which suggesting that the stock is 64.66% more volatile than S&P 500. In comparison InflaRx NV has a beta of 1.457, suggesting its more volatile than the S&P 500 by 45.659%.
-
Which is a Better Dividend Stock CZMWY or IFRX?
Carl Zeiss Meditec AG has a quarterly dividend of $0.65 per share corresponding to a yield of 2.03%. InflaRx NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Carl Zeiss Meditec AG pays 18.62% of its earnings as a dividend. InflaRx NV pays out -- of its earnings as a dividend. Carl Zeiss Meditec AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CZMWY or IFRX?
Carl Zeiss Meditec AG quarterly revenues are $623.3M, which are larger than InflaRx NV quarterly revenues of $27.8K. Carl Zeiss Meditec AG's net income of $32.2M is higher than InflaRx NV's net income of -$14.3M. Notably, Carl Zeiss Meditec AG's price-to-earnings ratio is 17.75x while InflaRx NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Carl Zeiss Meditec AG is 1.13x versus 276.31x for InflaRx NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CZMWYCarl Zeiss Meditec AG1.13x 17.75x $623.3M $32.2M IFRXInflaRx NV276.31x -- $27.8K -$14.3M
-
Which has Higher Returns CZMWY or IMTX?
Immatics NV has a net margin of 5.16% compared to Carl Zeiss Meditec AG's net margin of -974.45%. Carl Zeiss Meditec AG's return on equity of 7.44% beat Immatics NV's return on equity of -25.21%.
Company Gross Margin Earnings Per Share Invested Capital CZMWYCarl Zeiss Meditec AG52.71% $0.36 $2.3B IMTXImmatics NV-- -$0.49 $508.8M -
What do Analysts Say About CZMWY or IMTX?
Carl Zeiss Meditec AG has a consensus price target of --, signalling downside risk potential of --. On the other hand Immatics NV has an analysts' consensus of $19.13 which suggests that it could grow by 90.11%. Given that Immatics NV has higher upside potential than Carl Zeiss Meditec AG, analysts believe Immatics NV is more attractive than Carl Zeiss Meditec AG.
Company Buy Ratings Hold Ratings Sell Ratings CZMWYCarl Zeiss Meditec AG0 0 0 IMTXImmatics NV9 0 0 -
Is CZMWY or IMTX More Risky?
Carl Zeiss Meditec AG has a beta of 1.647, which suggesting that the stock is 64.66% more volatile than S&P 500. In comparison Immatics NV has a beta of 1.359, suggesting its more volatile than the S&P 500 by 35.865%.
-
Which is a Better Dividend Stock CZMWY or IMTX?
Carl Zeiss Meditec AG has a quarterly dividend of $0.65 per share corresponding to a yield of 2.03%. Immatics NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Carl Zeiss Meditec AG pays 18.62% of its earnings as a dividend. Immatics NV pays out -- of its earnings as a dividend. Carl Zeiss Meditec AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CZMWY or IMTX?
Carl Zeiss Meditec AG quarterly revenues are $623.3M, which are larger than Immatics NV quarterly revenues of $6.1M. Carl Zeiss Meditec AG's net income of $32.2M is higher than Immatics NV's net income of -$59.1M. Notably, Carl Zeiss Meditec AG's price-to-earnings ratio is 17.75x while Immatics NV's PE ratio is 42.21x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Carl Zeiss Meditec AG is 1.13x versus 13.44x for Immatics NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CZMWYCarl Zeiss Meditec AG1.13x 17.75x $623.3M $32.2M IMTXImmatics NV13.44x 42.21x $6.1M -$59.1M
-
Which has Higher Returns CZMWY or MDGEF?
Medigene AG has a net margin of 5.16% compared to Carl Zeiss Meditec AG's net margin of --. Carl Zeiss Meditec AG's return on equity of 7.44% beat Medigene AG's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CZMWYCarl Zeiss Meditec AG52.71% $0.36 $2.3B MDGEFMedigene AG-- -- -- -
What do Analysts Say About CZMWY or MDGEF?
Carl Zeiss Meditec AG has a consensus price target of --, signalling downside risk potential of --. On the other hand Medigene AG has an analysts' consensus of -- which suggests that it could fall by --. Given that Carl Zeiss Meditec AG has higher upside potential than Medigene AG, analysts believe Carl Zeiss Meditec AG is more attractive than Medigene AG.
Company Buy Ratings Hold Ratings Sell Ratings CZMWYCarl Zeiss Meditec AG0 0 0 MDGEFMedigene AG0 0 0 -
Is CZMWY or MDGEF More Risky?
Carl Zeiss Meditec AG has a beta of 1.647, which suggesting that the stock is 64.66% more volatile than S&P 500. In comparison Medigene AG has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock CZMWY or MDGEF?
Carl Zeiss Meditec AG has a quarterly dividend of $0.65 per share corresponding to a yield of 2.03%. Medigene AG offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Carl Zeiss Meditec AG pays 18.62% of its earnings as a dividend. Medigene AG pays out -- of its earnings as a dividend. Carl Zeiss Meditec AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CZMWY or MDGEF?
Carl Zeiss Meditec AG quarterly revenues are $623.3M, which are larger than Medigene AG quarterly revenues of --. Carl Zeiss Meditec AG's net income of $32.2M is higher than Medigene AG's net income of --. Notably, Carl Zeiss Meditec AG's price-to-earnings ratio is 17.75x while Medigene AG's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Carl Zeiss Meditec AG is 1.13x versus -- for Medigene AG. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CZMWYCarl Zeiss Meditec AG1.13x 17.75x $623.3M $32.2M MDGEFMedigene AG-- -- -- --
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 29x
Alerts
Buy
77
RNG alert for Feb 21
RingCentral, Inc. [RNG] is up 34.37% over the past day.
Sell
9
FROG alert for Feb 21
JFrog Ltd. [FROG] is down 24.98% over the past day.
Buy
72
SNSE alert for Feb 21
Sensei Biotherapeutics, Inc. [SNSE] is up 23.81% over the past day.
